MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3

Cancer

Volumn 118, Issue 13, 2012, Pages 3365-3376

  Feng, Bing ^a   Wang, Rui ^a   Song, Hai Zhu ^a   Chen, Long Bang ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Chemoresistance; Docetaxel; E2F3; Lung adenocarcinoma; MiR 200b

Indexed keywords

DOCETAXEL; MESSENGER RNA; MICRORNA 200B; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F3;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CARCINOMA CELL; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN RNA BINDING; PROTEIN TARGETING; RNA ANALYSIS; RNA SEQUENCE; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; UPREGULATION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; E2F3 TRANSCRIPTION FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MICRORNAS; MIDDLE AGED; PROGNOSIS; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862519692     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26560     Document Type: Article

References (47)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108. (Pubitemid 40372904)
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96. (Pubitemid 351521864)
3. Yvon AM, Wadsworth P, Jordan MA,. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell. 1999; 10: 947-959. (Pubitemid 29193723)
4. Wang TH, Wang HS, Soong YK,. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 2000; 88: 2619-2628.
5. Yu H,. Regulation of APC-Cdc20 by the spindle checkpoint. Curr Opin Cell Biol. 2002; 14: 706-714. (Pubitemid 35476850)
6. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG, Kruh GD,. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res. 2004; 64: 4927-4930. (Pubitemid 38924539)
7. Miyoshi Y, Taguchi T, Kim SJ, Tamaki Y, Noguchi S,. Prediction of response to docetaxel by immunohistochemical analysis of CYl73A4 expression in human breast cancers. Breast Cancer. 2005; 12: 11-15.
8. Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A. 2005; 102: 8315-8320. (Pubitemid 40800086)
9. Ooe A, Kato K, Noguchi S,. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers. Breast Cancer Res Treat. 2007; 101: 305-315. (Pubitemid 46169885)
10. Brown I, Shalli K, McDonald SL, et al. Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells. Breast Cancer Res. 2004; 6: R601-R607.
11. Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F,. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle. 2006; 5: 1001-1007.
12. Chun E, Lee KY,. Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2004; 315: 771-779. (Pubitemid 38229409)
13. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L,. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1 signal pathways increases resistance to apoptosis by up-regulating Survivin gene expression. J Biol Chem. 2006; 281: 25903-25914. (Pubitemid 44401796)
14. Kastl L, Brown I, Schofield AC,. miRNA-34a is associated with docetaxel resistance in human breast cancer cells [published online ahead of print March 12, 2011]. Breast Cancer Res Treat. doi: 10.1007/s10549-011-1424-3.
15. Behm-Ansmant I, Rehwinkel J, Izaurralde E,. MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harb Symp Quant Biol. 2006; 71: 523-530.
16. Gordeladze JO, Djouad F, Brondello JM, et al. Concerted stimuli regulating osteo-chondral differentiation from stem cells: phenotype acquisition regulated by microRNAs. Acta Pharmacol Sin. 2009; 30: 1369-1384.
17. Wu F, Yang Z, Li G,. Role of specific microRNAs for endothelial function and angiogenesis. Biochem Biophys Res Commun. 2009; 386: 549-553.
18. Skaftnesmo KO, Prestegarden L, Micklem DR, Lorens JB,. MicroRNAs in tumorigenesis. Curr Pharm Biotechnol. 2007; 8: 320-325. (Pubitemid 350268190)
19. Ambros V,. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 2003; 113: 673-676. (Pubitemid 36724931)
20. Blower PE, Verducci JS, Lin S, et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther. 2007; 6: 1483-1491. (Pubitemid 46954015)
21. Zhu W, Shan X, Wang T, Shu Y, Liu P,. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer. 2010; 127: 2520-2529.
22. Boni V, Bitarte N, Cristobal I, et al. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol Cancer Ther. 2010; 9: 2265-2275.
23. Pan YZ, Morris ME, Yu AM,. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein(BCRP/ABCG2) in human cancer cells. Mol Pharmacol. 2009; 75: 1374-1379.
24. Shi GH, Ye DW, Yao XD, et al. Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin. 2010; 31: 867-873.
25. Rui W, Bing F, Hai-Zhu S, Wei D, Long-Bang C,. Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J Cell Mol Med. 2010; 14: 206-214.
26. Xia W, Li J, Chen L, et al. MicroRNA-200b regulates cyclin D1 expression and promotes S-phase entry by targeting RND3 in HeLa cells. Mol Cell Biochem. 2010; 344: 261-266.
27. Chi W, Ying Z, Tao S, Liang H, Zhen-Jiang M, Xiang X,. miR-200b over-expression down-regulates Bcl-2 expression and inhibits cell proliferation in human gastric cancer cell line MGC-803. Shijie Huaren Xiaohua Zazhi. 2010; 18: 2077-2083.
28. Hai S, Long-Bang C,. Mechanism of drug resistance identified in human lung adenocarcinoma cell line SPC-A1 selected for resistance to docetaxel. Chin J Cancer Res. 2009; 21: 207-216.
29. Tsang WP, Kwok TT,. The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis. 2009; 30: 953-959.
30. Yang F, Sarangarajan R, Le Poole IC, Medrano EE, Boissy RE,. The cytotoxicity and apoptosis induced by 4-tertiary butylphenol in human melanocytes are independent of tyrosinase activity. Invest Dermatol. 2000; 114: 157-164. (Pubitemid 30195989)
31. Zhang SZ, Pan FY, Xu JF, et al. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther. 2005; 4: 1577-1584.
32. Liu P, Chen L, Huang X,. The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo. Cancer Biother Radiopharm. 2009; 24: 91-98.
33. Hu Z, Lin D, Yuan J, et al. Over-expression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res. 2005; 11: 4646-4652. (Pubitemid 41557181)
34. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007; 67: 8699-8707. (Pubitemid 47437445)
35. Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006; 130: 2113-2129. (Pubitemid 43816961)
36. Bracken CP, Gregory PA, Kolesnikoff N, et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008; 68: 7846-7854.
37. Cooper CS, Nicholson AG, Foster C, et al. Nuclear over-expression of the E2F3 transcription factor in human lung cancer. Lung Cancer. 2006; 54: 155-162. (Pubitemid 44764914)
38. Wu L, Timmers C, Maiti B, et al. The E2F1-3 transcription factors are essential for cellular proliferation. Nature. 2001; 414: 457-462. (Pubitemid 34173728)
39. Sharma N, Timmers C, Trikha P, Saavedra HI, Obery A, Leone G,. Control of the p53-p21CIP1 Axis by E2f1, E2f2, and E2f3 is essential for G1/S progression and cellular transformation. J Biol Chem. 2006; 281: 36124-36131. (Pubitemid 46041346)
40. Zhu W, Giangrande PH, Nevins JR,. E2Fs link the control of G1/S and G2/M transcription. EMBO J. 2004; 23: 4615-4626. (Pubitemid 39657861)
41. He L, Yang H, Ma Y, Pledger WJ, Cress WD, Cheng JQ,. Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression. J Biol Chem. 2008; 283: 31012-31020.
42. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA,. Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem. 2004; 279: 40511-40520. (Pubitemid 39287642)
43. Fu J, Bian M, Jiang Q, Zhang C,. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res. 2007; 5: 1-10.
44. Anand S, Penrhyn-Lowe S, Venkitaraman AR,. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell. 2003; 3: 51-62. (Pubitemid 37443890)
45. Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 2001; 40: 1117-1123. (Pubitemid 32108606)
46. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998; 396: 580-584. (Pubitemid 28563719)
47. Sudo T, Nitta M, Saya H, Ueno NT,. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res. 2004; 64: 2502-2508. (Pubitemid 38523906)